ABSTRACT
Living-donor liver transplantation (LDLT) initially gained favor in the late 1980s in pediatric patients because of the shortage of livers from deceased donors (1,2). Since then, left hepatic lobe LDLT and left lateral segment LDLT have both become safe and effective alternatives to deceased donor liver transplantation (DDLT), with similar recipient morbidity and mortality (3). In fact, LDLT now accounts for about 30% of all liver transplantations performed in children in the United States (4).
